After very successful results with Medilevel's system HIPR, there was a desire for a similar system for titration and follow-up of antidepressant drugs. Based on these wishes, we developed SENO. Medilevel has been responsible for the technical development and staff from some of Sweden's regions have been responsible for the medical competence. In addition to the follow-up of the daily moon, SENO also contains the self-assessment forms MADRS-S and MFQ13. SENO is now ready to be tested and evaluated. This will be done in 2021, in two planned studies.
The Gävleborg region is now starting a study with our SENO system. With the help of the prize money from the prize of the Svea Prize, the region will in the autumn of 2020 and the spring of 2021 carry out a study that includes 60 patients (30 children and 30 adults) as well as affected doctors and nurses. The study will evaluate the experience of patients and their families, as well as measure and clarify the efficiency gains and patient benefit. The study is expected to last for six months and the results will be presented in the autumn of 2021.
SENO is pilot tested at an adult psychiatric clinic in Västra Götalandsregionen to evaluate how a digital solution for follow-up of antidepressant medication is experienced by patients, and whether it can improve the outcome of treatment.
More information about the studies will be presented on an ongoing basis.